The AHA acknowledged that complementary and alternative medicines are widely used by heart failure patients but warned that there is limited scientific evidence to support their efficacy.
Jennifer N. Tovar, PharmD Candidate
Advertisement
Articles by Jennifer N. Tovar, PharmD Candidate
Risankizumab-rzaa is the first and only specific IL-23 inhibitor approved to treat moderately to severely active Crohn disease in adults.
Advertisement
Latest Updated Articles
AHA Statement Reviews Benefits, Risks of Alternative Therapies for Heart FailurePublished: October 1st 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
3
Pharmacy Policy Updates for October 2025
4
Expert: Tariff Increases May Pressure Pharmacy Margins and Supply Chains
5
